The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Secukinumab Effective for Psoriatic Arthritis

Secukinumab Effective for Psoriatic Arthritis

October 12, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270Although many patients with psoriatic arthritis benefit from treatment with anti-tumor necrosis factor (anti-TNF), some find their side effects unacceptable. This aversion has led researchers to search for an alternative therapy that may be better tolerated. A Phase 2 study of the anti-interleukin 17A monoclonal antibody secukinumab found that it improved the signs and symptoms of psoriatic arthritis. The results of the Phase 3 study were reported in the October 2015 issue of the New England Journal of Medicine.

You Might Also Like
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
Also By This Author
  • Why Rheumatologists Should Care about Zika: How It’s Transmitted & Spreading in the U.S.

Philip J. Mease, MD, a rheumatologist at the University of Washington in Seattle, and colleagues published the results of the double-blind study, which included 606 patients who were randomized into three study groups. The Phase 3 study revealed that secukinumab (150 mg or 75 mg doses) was more effective than placebo in treatment of psoriatic arthritis, according to all of the prespecified primary and secondary endpoints. It was also significantly better than placebo at improving patient-reported physical functioning and quality of life.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR20 response rates at Week 24 were significantly higher in the groups receiving secukinumab than in those receiving placebo. The ACR50 response and joint structural damage were also significantly better in the treatment groups when compared with placebo. The improvements continued through Week 52 and were independent of previous patient exposure to anti-TNF therapy. Specifically, the investigators estimated that, at Week 52, >50% of the patients in the treatment group had an ACR20 response.

“We used a rigorous assessment of efficacy at Week 24, with the imputation of missing data as no response, which provided a conservative estimate,” elaborate the authors in their discussion. “One limitation of our study is that it did not include assessment of axial disease. In addition, the use of the same high intravenous loading dose in the two secukinumab groups made it difficult to identify any potential dose–response relationships.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers reported adverse events in 64.9% of patients receiving 150 mg secukinumab, 60.4% of patients receiving 75 mg secukinumab and 58.4% of patients receiving placebo. Less than 5% of patients had adverse events that led to discontinuation of secukinumab. However, treatment with secukinumab was associated with increased infections, including candida. The treatment group also had four patients who experienced stroke (0.6 per 100 patient-years) and two patients who experienced myocardial infarction (0.3 per 100 patient-years). In contrast, none of the patients in the placebo group experienced a cardiovascular event. The maximum exposure to secukinumab was 103 weeks, and the patients had a mean exposure of 438.5 days. Thus, the investigators noted that the study was not long enough to evaluate adverse effects associated with long-term use.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Anti-TNF, anti-TNF agent, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.